Leukemia Posts on Medivizor
Navigation Menu

Leukemia Posts on Medivizor

Long-term safety and effectiveness of acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in patients with chronic lymphocytic leukemia

Long-term safety and effectiveness of acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in patients with chronic lymphocytic leukemia

Posted by on Apr 26, 2022 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the long-term safety and effectiveness of acalabrutinib (Calquence) with or without obinutuzumab (Gazyva) versus obinutuzumab with chlorambucil (Leukeran) in patients with chronic lymphocytic leukemia (CLL) that have never received treatment (treatment-naive).  This study concluded that the...

Read More

Evaluating the safety and effectiveness of optimized conformal total body irradiation in children with with blood cancer who received TCRαβ/CD19-depleted grafts

Evaluating the safety and effectiveness of optimized conformal total body irradiation in children with with blood cancer who received TCRαβ/CD19-depleted grafts

Posted by on Apr 10, 2022 in Leukemia | 0 comments

In a nutshell The study aimed to investigate optimized conformal (OC) total body irradiation (TBI) in pediatric patients with blood cancers who received further chemotherapy and allogeneic hematopoietic stem cell transplant (alloHSCT) with TCRαβ/CD19 depletion.   This study concluded that OC-TBI is a...

Read More

Evaluating antibody response rates of patients with chronic lymphocytic leukemia to a third dose of mRNA COVID-19 vaccine

Evaluating antibody response rates of patients with chronic lymphocytic leukemia to a third dose of mRNA COVID-19 vaccine

Posted by on Mar 20, 2022 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the antibody response to a third mRNA COVID-19 vaccine of patients with chronic lymphocytic leukemia (CLL) who had failed to achieve an antibody response after the standard two-dose vaccination regimen.  This study concluded that approximately a quarter of patients responded to the third...

Read More

Evaluating the safety and effectiveness of blinatumomab for the treatment of children with relapsed or refractory B-cell acute lymphoblastic leukemia.

Evaluating the safety and effectiveness of blinatumomab for the treatment of children with relapsed or refractory B-cell acute lymphoblastic leukemia.

Posted by on Mar 20, 2022 in Leukemia | 0 comments

In a nutshell This study evaluated the safety and effectiveness of blinatumomab (Blincyto) for the treatment of children with relapsed or refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL). The data showed that blinatumomab was safe and effective for these patients. Some background B-ALL is a type of cancer in which the body makes...

Read More

What is the usefulness of measurable residual disease in patients with acute myeloid leukemia treated with venetoclax and azacitidine?

What is the usefulness of measurable residual disease in patients with acute myeloid leukemia treated with venetoclax and azacitidine?

Posted by on Mar 15, 2022 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the outcomes for acute myeloid leukemia (AML) patients treated with venetoclax (Venclexta) and azacitidine (Vidaza) who achieved complete remission (CR) and minimal measurable residual disease (MRD) after treatment.  This study concluded that patients who achieved both CR and minimal...

Read More

Vacations for Adult Cancer Patients: Update

Vacations for Adult Cancer Patients: Update

Posted by on Mar 4, 2022 in Blog, Breast cancer, Colorectal cancer, Hodgkin's lymphoma, Leukemia, Lung cancer, Lymphoma, Melanoma, Multiple Myeloma, Non-Hodgkin lymphoma, Prostate cancer | 0 comments

Two of our most popular previous blog posts described free vacation opportunities for adults with cancer. Given the uncertainty of the past two years, we thought it was time for an update.  Here is a short list of organizations that have made it their mission to provide needed respite to those affected by cancer. Each has been verified to have...

Read More

Evaluating therapies after CAR-T Cell treatment in patients with relapsed and refractory ALL

Evaluating therapies after CAR-T Cell treatment in patients with relapsed and refractory ALL

Posted by on Feb 6, 2022 in Leukemia | 0 comments

In a nutshell The study aimed to investigate if allogeneic hematopoietic stem cell transplant (alloHSCT) was a suitable treatment strategy for patients with relapsed/refractory (r/r) acute lymphoblastic leukemia (ALL) after chimeric antigen receptor (CAR) T-cell therapy.   This study concluded that this was a suitable treatment...

Read More

Treating chronic lymphocytic leukemia/small lymphocytic lymphoma with rituximab and high-dose methylprednisolone

Treating chronic lymphocytic leukemia/small lymphocytic lymphoma with rituximab and high-dose methylprednisolone

Posted by on Feb 6, 2022 in Leukemia | 0 comments

In a nutshell This study aimed to investigate using rituximab (Rituxan) and high-dose methylprednisolone (HDMP; Medrol) as a treatment for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).   This study concluded that this treatment is a good option for elderly and frail patients and can work as a bridge to...

Read More

Clofarabine-fludarabine-busulfan conditioning before hematopoietic stem cell therapy in children with acute leukemia

Clofarabine-fludarabine-busulfan conditioning before hematopoietic stem cell therapy in children with acute leukemia

Posted by on Jan 23, 2022 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the combination of clofarabine (Clolar)-fludarabine (Fludara)-busulfan (Busulfex) as a conditioning regime in hematopoietic stem cell transplant (HSCT) for children with acute leukemia.  This study concluded that this combination is safe and effective in these patients.   Some...

Read More

Updated NCCN guidelines for acute lymphoblastic leukemia.

Updated NCCN guidelines for acute lymphoblastic leukemia.

Posted by on Jan 16, 2022 in Leukemia | 0 comments

In a nutshell These guidelines aimed to update treatment options for patients with Philadelphia chromosome-positive (Ph+) and negative (Ph-) acute lymphoblastic leukemia (ALL). Some background Acute lymphoblastic leukemia (ALL) represents 75% to 80% of acute leukemia among children and so is the most common form of childhood leukemia. It represents...

Read More

Investigating minimal residual disease and long-term outcomes in patients with chronic lymphocytic leukemia who have been treated with venetoclax-obinutuzumab

Investigating minimal residual disease and long-term outcomes in patients with chronic lymphocytic leukemia who have been treated with venetoclax-obinutuzumab

Posted by on Dec 31, 2021 in Leukemia | 0 comments

In a nutshell This study aimed to investigate minimal residual disease (MRD) and long-term outcomes of patients with chronic lymphocytic leukemia (CLL) who were treated with venetoclax (Venclexta) and obinutuzumab (Gazyva).  This study concluded that this treatment leads to an effective MRD reduction and has...

Read More

Evaluating long-term outcomes after low dose pegylated interferon-α combined with dasatinib in patients with chronic phase chronic myeloid leukemia

Evaluating long-term outcomes after low dose pegylated interferon-α combined with dasatinib in patients with chronic phase chronic myeloid leukemia

Posted by on Dec 31, 2021 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the long-term safety and effectiveness of low-dose pegylated (PEG) interferon-α (IFN-α) combined with dasatinib in patients with chronic-phase (CP) chronic myeloid leukemia (CML).  This study concluded that this treatment was safe and effective in the long-term in these...

Read More